Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
With
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Age
1–8
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completed 12 weeks of treatment in the MAP0010-CL-P301 study.
Patient, parent, and guardian (as appropriate) are willing for child to undergo all study procedures and willing to sign the informed consent and assent, as appropriate.
You may not be if
Less than 80% compliance with either study treatment and/or other study procedures (e.g., completion of symptom e-diary) in the MAP0010-CL-P301 Study.
Clareo Health | A Study of 2 Doses of MAP0010 in Asthmatic Children
